IRD Projected Dividend Yield
Opus Genetics Inc ( NASDAQ : IRD )Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Co.'s primary product candidate, Nyxol® Eye Drops, is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Co.'s second product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases such as diabetic retinopathy and diabetic macular edema which, if left untreated, can result in permanent visual acuity loss and eventual blindness. 20 YEAR PERFORMANCE RESULTS |
IRD Dividend History Detail IRD Dividend News IRD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |